Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
J Vasc Surg. 2012 Nov;56(5):1355-62; discussion 1362. doi: 10.1016/j.jvs.2012.04.066. Epub 2012 Sep 19.
Vascular malformations are a rare and complex group of lesions which may present serious pitfalls in diagnosis and management. We sought to evaluate the efficacy and safety of our imaging protocol and therapeutic algorithm in the treatment of low-flow and high-flow vascular malformations in a large series of patients.
A prospective database of all patients treated by the multidisciplinary vascular malformation team at our institution between 2006 and 2011 was reviewed. Management decisions were based on patients' clinical profile as well as critical lesion characteristics, and included conservative care, sclerotherapy, embolization, surgical resection, or a combination of these modalities. Treatment goals and expectations were established by the patient and physician at the time of initial evaluation. An outcomes grading system based on patient- and physician-derived treatment goals and assessment of response to management was applied (1 = worse; 2 = unchanged, 3 = significantly improved, 4 = completely resolved), and postprocedural complications were identified.
The 136 vascular malformations in 135 patients included 59 (43.7%) males and 76 (56.3%) females, ranging in age from under 1 year to 68 years (mean, 25.3 ± 17.0 years). In order to facilitate application of the therapeutic algorithm, all patients underwent dynamic contrast-enhanced magnetic resonance imaging to determine critical lesion characteristics, including flow quality and lesion extension. Of the 105 low-flow vascular malformations (LFVM), 23 (21.9%) were managed conservatively, 38 (36.2%) were treated with sclerotherapy (sodium tetradecyl sulfate, polidocanol, and/or ethanol), 18 (17.1%) were surgically resected, and eight (7.6%) were managed with a combination of modalities. Of the 31 high-flow vascular malformations (HFVM), eight (25.8%) were managed conservatively, eight (25.8%) were treated with transcatheter arterial embolization, six (19.4%) required embolization followed by sclerotherapy, and five (16.1%) were primarily resected. Patients in all groups managed conservatively had minimal alteration in status. Response to sclerotherapy in the LFVM group resulted in improvement in 32 (84.2%) patients, surgical resection resulted in improvement in 16 (88.9%) patients, and combination therapy resulted in improvement in eight (100%) patients. Treatment with embolization in the HFVM group resulted in improvement in seven (87.5%) patients, while combination therapy resulted in improvement in six (100%), and surgical resection led to improvement in four (80%). Complications were observed in six (6.8%) patients treated for LFVMs (0 with sodium tetradecyl sulfate or polidocanol, four with ethanol, two with resection), and two (7.4%) patients treated for HFVMs with embolization or combination therapy.
In this large cohort of vascular malformation patients, implementation of the proposed diagnostic and therapeutic algorithms in a multidisciplinary setting resulted in favorable outcomes with an acceptable complication rate in this challenging patient population.
血管畸形是一组罕见且复杂的病变,在诊断和治疗方面可能存在严重的问题。我们旨在评估我们的影像学方案和治疗算法在治疗大量患者的低流量和高流量血管畸形中的疗效和安全性。
回顾了 2006 年至 2011 年我院多学科血管畸形治疗团队治疗的所有患者的前瞻性数据库。治疗决策基于患者的临床特征和关键病变特征,包括保守治疗、硬化治疗、栓塞、手术切除或这些方法的联合应用。在初始评估时,患者和医生确定了治疗目标和期望。应用了一种基于患者和医生治疗目标以及对管理反应评估的结果分级系统(1=更差;2=不变,3=明显改善,4=完全缓解),并确定了术后并发症。
135 例患者中的 136 个血管畸形包括 59 例(43.7%)男性和 76 例(56.3%)女性,年龄从 1 岁以下到 68 岁(平均 25.3±17.0 岁)。为了便于应用治疗算法,所有患者均接受动态对比增强磁共振成像以确定关键病变特征,包括血流质量和病变范围。105 个低流量血管畸形(LFVM)中,23 个(21.9%)保守治疗,38 个(36.2%)接受硬化治疗(十四烷基硫酸钠、聚多卡醇和/或乙醇),18 个(17.1%)手术切除,8 个(7.6%)采用联合治疗。31 个高流量血管畸形(HFVM)中,8 个(25.8%)保守治疗,8 个(25.8%)经导管动脉栓塞治疗,6 个(19.4%)栓塞后硬化治疗,5 个(16.1%)直接切除。所有保守治疗组的患者病情均有轻微改变。LFVM 组的硬化治疗反应导致 32 例(84.2%)患者改善,手术切除导致 16 例(88.9%)患者改善,联合治疗导致 8 例(100%)患者改善。HFVM 组栓塞治疗导致 7 例(87.5%)患者改善,联合治疗导致 6 例(100%)患者改善,手术切除导致 4 例(80%)患者改善。在接受 LFVM 治疗的 6 例(6.8%)患者中观察到并发症(0 例使用十四烷基硫酸钠或聚多卡醇,4 例使用乙醇,2 例接受切除),在接受栓塞或联合治疗的 2 例 HFVM 患者中观察到 2 例(7.4%)并发症。
在这个大型血管畸形患者队列中,在多学科环境中实施提出的诊断和治疗算法,在这个具有挑战性的患者群体中,取得了良好的结果,并具有可接受的并发症发生率。